FDA June 2026 enforcement update — compounding pharmacies
Pinned because it affects plans people have already made, not because it is dramatic. Everything below is what is confirmed as of today.
This post is the record, and it will be edited as things change — with the change noted rather than substituted. If you have something firmer than what is here, a document or a date or a first-hand account, post it and it goes in with credit.
Read it this way:
- What is stated is confirmed; what is uncertain is marked as uncertain
- Anything time-sensitive is worth verifying yourself before you act on it
- The replies below carry the corrections, so read them before asking
Nothing here is advice about your situation, and the situation is still moving.
Great question, and one that doesn't get explained well enough. Here's the short version:
503A pharmacies are your traditional compounding pharmacies. They operate under state pharmacy boards, require a patient-specific prescription, and compound medications on a per-patient basis. Think of your local compounding pharmacy down the street.
503B outsourcing facilities were created by the Drug Quality and Security Act of 2013 (after the NECC meningitis disaster that killed 76 people). They're registered with the FDA, can produce larger batches without patient-specific prescriptions, and are subject to FDA cGMP inspections.
Key differences:
- 503B facilities must report adverse events to FDA
- 503B must comply with cGMP (current Good Manufacturing Practice)
- 503A are state-regulated; 503B are federally regulated
- 503B can ship across state lines more freely
Neither is automatically "safer." A well-run 503A can be excellent. A sloppy 503B can be dangerous. But the regulatory framework around 503B is more rigorous on paper.
Previously posted:Neither is automatically "safer." A well-run 503A can be excellent.
This is the right answer but I want to push back slightly. In practice, 503B facilities are inspected by FDA and must follow USP <797> sterile compounding standards with full environmental monitoring, media fills, and personnel qualification testing. Most 503A pharmacies are inspected by state boards that vary WILDLY in their rigor.
I've worked in both settings. The 503B I was at had ISO 5 cleanrooms, continuous viable and non-viable air monitoring, and every batch underwent potency testing via HPLC and endotoxin testing via LAL. The 503A I started at? The "cleanroom" was a glorified closet with a laminar flow hood.
If you have the choice, go 503B. Period. 🏥
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsCounterpoint: some of the biggest compounding scandals have come from 503B facilities. Remember the FDA warning letters to multiple outsourcing facilities in 2024-2025? Several 503B operations were found to have sub-potent products and contamination issues.
The label doesn't guarantee quality. Due diligence does.
makes a fair point. The NECC disaster that created the 503B category was essentially a pharmacy operating as a manufacturer without oversight. The category exists because the old system failed.
My recommendation for patients:
- Check if the pharmacy is on FDA's registered outsourcing facility list
- Ask for a Certificate of Analysis (COA) for your specific batch
- Verify the COA includes potency (HPLC), sterility, endotoxin (LAL), and beyond-use dating
- Check your state board of pharmacy for any disciplinary actions
Whether it's 503A or 503B, these steps protect you.